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Abstract
More than 200 heterozygous mutations in the type 2 BMP receptor gene, BMPR2, have been identified in patients
with Heritable Pulmonary Arterial Hypertension (HPAH). More severe clinical outcomes occur in patients with BMPR2
mutations by-passing nonsense-mediated mRNA decay (NMD negative mutations). These comprise 40% of HPAH
mutations and are predicted to express BMPR2 mutant products. However expression of endogenous NMD negative
BMPR2 mutant products and their effect on protein trafficking and signaling function have never been described.
Here, we characterize the expression and trafficking of an HPAH-associated NMD negative BMPR2 mutation that
results in an in-frame deletion of BMPR2 EXON2 (BMPR2ΔEx2) in HPAH patient-derived lymphocytes and in
pulmonary endothelial cells (PECs) from mice carrying the same in-frame deletion of Exon 2 (Bmpr2ΔEx2/+ mice). The
endogenous BMPR2ΔEx2 mutant product does not reach the cell surface and is retained in the endoplasmic
reticulum. Moreover, chemical chaperones 4-PBA and TUDCA partially restore cell surface expression of
Bmpr2ΔEx2 in PECs, suggesting that the mutant product is mis-folded. We also show that PECs from Bmpr2ΔEx2/+
mice have defects in the BMP-induced Smad1/5/8 and Id1 signaling axis, and that addition of chemical chaperones
restores expression of the Smad1/5/8 target Id1. These data indicate that the endogenous NMD negative
BMPRΔEx2 mutant product is expressed but has a folding defect resulting in ER retention. Partial correction of this
folding defect and restoration of defective BMP signaling using chemical chaperones suggests that protein-folding
agents could be used therapeutically in patients with these NMD negative BMPR2 mutations.
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Introduction
Despite modern vasodilator treatments, patients with
Pulmonary Arterial Hypertension (PAH) only have a 50% 5-
year survival[1]. For this reason there was considerable interest
in the discovery that patients with a rare form of autosomal
dominant, Heritable Pulmonary Arterial Hypertension (HPAH)
carry mutations in the BMPR2 (bone morphogenetic protein
receptor 2) gene [2,3]. BMPR2 is one of three Type 2 BMP
pathway receptors. Once stimulated by BMP ligands BMPR2
forms hetero-tetrameric complexes with Type I receptors at the
cell surface (reviewed in 4,5). These receptor complexes then
activate the canonical SMAD 1/5/8 pathway, which in turn
leads to the transcriptional regulation of target genes such as
ID1[6]. Several SMAD-independent pathways including ERK1/2
and p38 MAPK, PI3K and PKC are also activated downstream
of BMPR2, but unlike canonical SMAD signaling, activation of
these pathways is often cell type and context dependent [5,7].
Although the mechanism by which defects in the BMP signaling
contribute to HPAH remains elusive, BMP-signaling defects
associated with mutations in BMPR2 have been implicated in
abnormal pulmonary vascular cell proliferation, remodeling and
vascular tone [8-14]. These diverse roles in regulating the
pulmonary vasculature and the defects in this pathway
detected in patients with HPAH, suggest that strategies to
correct BMP signaling defects may have long-term disease
modifying effects. To this end, approaches have been
developed to enhance expression of the wild type BMPR2
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allelic product in HPAH patients [15]. In addition, drugs that
promote read-through of pre-termination codons associated
with BMPR2 mutation that result in non-sense mediated decay
of the mutant mRNA product, also increase expression of
functional BMPR2 mutant products in cells from patients with
HPAH [16,17]. In these studies we take an alternative
approach to correct BMP signaling defects by correcting
abnormal trafficking of a BMPR2 mutant protein product.
Over 200 unique mutation sites have been identified
throughout the open reading frame of the BMPR2 gene in
HPAH patients [18,19]. The majority of these mutations are
non-sense or frame-shift mutations, leading to degradation of
an unstable mRNA by nonsense mediated mRNA decay (NMD
positive mutation), ultimately leading to haploinsufficiency [20].
However, 40% of HPAH-associated BMPR2 mutations are mis-
sense or in-frame deletion mutations, predicted to produce
stable mRNA transcripts and express mutant protein products.
Clinical data indicate that HPAH patients with these mutations
have a more severe form of HPAH with reduced time until lung
transplant and an earlier age of diagnosis[20], suggesting that
these mutant protein products are expressed and may have
dominant negative effects on BMPR2 function. Previous
studies have characterized NMD negative BMPR2 mutations
using heterologous over-expression systems. These data
suggest that HPAH-associated missense mutations in the
ligand binding and kinase domains of BMPR2 are unable to
traffic to the cell surface [21,22], and that trafficking and
signaling can be restored using chemical chaperones [23].
These findings suggest that chemical chaperones, which
correct folding and restore function of mutant protein products
in a variety of heritable diseases including cystic fibrosis
[24,25], might be used as disease modifying agents by
restoring signaling function to some NMD negative BMPR2
mutations in patients with HPAH. However there is no
documented evidence that NMD negative BMPR2 mutant
proteins products are actually expressed endogenously in
patients with HPAH, and no data to indicate whether chemical
chaperones restore function in pulmonary vascular cells.
In these studies, we evaluate endogenous expression and
intracellular trafficking of BMPR2 mutant products in
lymphocytes from an HPAH patient with an NMD negative
BMPR2 mutation expressing an in-frame deletion of BMPR2
EXON 2, and in pulmonary endothelial cells (PECs) from mice
carrying the same mutation. We show that these mutant
receptor products are expressed, abnormally trafficked to the




Mice used in endothelial cell studies were approved by the
Vanderbilt University Institutional Animal Care and Use
Committee (Dr. Ron Emeson, IACUC chair) under protocol
number M/11/015 and were adherent with the National
Institutes of Health guidelines for care and use of laboratory
animals under Vanderbilt animal welfare assurance licence
number A3227-01.
The Vanderbilt University Medical Center Institutional Review
Boards approved use of control and HPAH patient-derived
lymphocytes and participants gave informed written consent for
use of their lymphocyte cultures for study (IRB #9401"Genetic
and Environmental Pathogenesis of PPH" RFA-HL-04-019, Dr.
James A.S. Muldowney, chair, Institutional Review Board
Health Sciences Committee #3).
Mouse lines
Endothelial cell lines were isolated from Bmpr2ΔEx2/+ mice
(mice described previously [26]). Studies were approved by the
Vanderbilt University Institutional Animal Care and Use
Committee (see above for ethics statement). Mice were
backcrossed onto a C57Bl/6J background for more than 9
generations. Genotyping was performed by PCR from ear
punch DNA using the following primers: Common forward
CCATGCTCTTTTGAAGATGG; Wild type reverse:
GTCCCCTTTTGATTTCTCCCA (producing a 1kB WT product);
and mutant reverse: GGCCGCTTTTCTGGATTCATC
(producing a 700bp mutant product). To create the ciEC lines,
Bmpr2ΔEx2/+ mice were bred with H-2Kb-tsA58 immorto mice
(immorto mice described previously [27]). Genotyping was
performed as described above with the additional PCR primers
for the immorto mice: forward:
AGCGCTTGTGTCGCCATTGTATTC and reverse:
GTCACACCACAGAAGTAAGGTTCC, producing a 1kb band.
Chemicals and Reagents
Sulfo-NHS-LC-Biotin and Streptavidin agarose conjugated
beads (Pierce/Thermo Scientific); Dio-Ac-LDL (Biomedical
Technologies Inc.); Endo-H and PNGase-F glycosidases (New
England Biolabs); Human recombinant BMP-2 (R&D Systems);
chemical chaperones sodium phenylbutyrate (4-PBA) and
Sodium taurourdeoxycholic acid (TUDCA) (Sigma-Aldrich). The
following antibodies were used for western blots: mouse
monoclonal anti-BMPR2 (clone 18, BD Biosciences) and anti-
β-actin (Sigma-Aldrich); rabbit polyclonal anti-phospho-Smad1
(Ser463, Ser 465) /5(Ser 463, 465) /8(Ser 426, 428), anti-
phospho-Akt(Ser 473), and anti-phospho-Erk1/2 (Thr 202, Tyr
204) (Cell Signaling). Affinity purified rabbit polyclonal anti-
BMPR2 antibodies were generated in house by immunizing
rabbits with keyhole limpet hemocyanin conjugated peptide
ASQNQERLCAFKDP (ASQ). Secondary antibodies were anti-
mouse horseradish peroxidase (HRP) and anti-rabbit-HRP
from KPL and Cell Signaling, respectively.
Cell Culture
Conditionally immortalized pulmonary endothelial cells
(ciPECs) were isolated, passaged and maintained as
previously described [8,28,29]. Briefly, cells were grown at
33°C in complete EGM-2MV media (LONZA) containing
10units/ml of interferon-γ (Peprotech). Prior to experimental
use, interferon-γ was removed and cells shifted from 33°C to
37°C for 2 days. HPAH patient-derived and normal control
immortalized lymphocytes were isolated as previously
described [16,30]. Cells were passaged and maintained in
1640 RPMI media (Gibco/Life Technologies) containing 20%
fetal bovine serum (FBS) (Sigma).
Mis-Trafficking of Endogenous BMPR2 Mutant Protein
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Isolation of Primary Pulmonary Endothelial Cells
(PECs)
Mouse pulmonary vasculature was perfused with phosphate
buffered saline (PBS) containing 2mM EDTA followed by
0.25% Trypsin-EDTA through the right ventricle. The lungs
were excised, minced, placed in a 60mm dish with 0.25%
Trypsin-EDTA and moved to a 37° degree incubator for 20-30
minutes. The lung block was removed and complete EGM-2MV
containing 5% FBS was then added to the dish to neutralize
trypsin. Cells were centrifuged and re-suspended in fresh
complete EGM-2MV with normacin (Invivogen). The cell
suspension was plated on 35mm dishes coated in 0.1% gelatin
and grown for 2-3 days before media was replaced. The cells
were identified as endothelial in origin based on morphology
and Dio-AC-LDL staining. Functional studies were carried out
in the cells by passage 2.
Western Blotting
Cells were lysed in ice cold lysis buffer (LB) made up of
25mM HEPES, 150mM NaCl, 5mM EDTA, 1% Triton X-100,
10% glycerol containing proteinase inhibitor cocktail and
phosphatase inhibitor cocktails 2 and 3 (Sigma). Protein
concentration was measured using the DC Protein Assay (Bio-
Rad). Western blots were performed as previously described
[31]. All primary antibodies were used at a dilution of 1:1000 in
5% nonfat dry milk in TBST (25mM Tris, 1M NaCl, 1% Tween
20), excepting phospho-specific antibodies which were diluted
1:1000 in 5% BSA in TBST. Secondary antibodies were diluted
1:2000 in 5% nonfat dry milk in TBST.
Cell signaling and chemical chaperone treatment
For signaling studies, cells were serum starved in EBM-2
media (Lonza) supplemented with 0.1% bovine serum albumin
(BSA) for 16 hours and then treated with 10ng/ml BMP2 for 4
hours. EBM-2 is the basal media used to make complete
EGM-2MV without addition of supplements, growth factors and
FBS. Chemical chaperones were added to confluent
monolayers of cells. 4-PBA and TUDCA were dissolved in
water and added to cells at the indicated concentrations 48
hours and 5 hours prior to biotinylation, respectively. For
functional studies, primary PECs were treated with 4-PBA at
1mM for 48 hours. Cells were serum starved for 16 hours, as
described above, and treated with 10ng/ml of BMP2 for 4 hours
before lysis.
Glycosidase Sensitivity Assay
Cells were lysed in LB and immunoprecipitated using Protein
G dynabeads (Life Technologies) conjugated to anti-BMPR2
antibody (Clone 18, BD) at room temperature for 15 minutes,
per the manufacturer’s directions. Immunoprecipitates were
washed 3 times with LB, denatured using de-glycosylation
buffer and subjected to Endo-H or PNGase-F digestion for 3
hours in a 37° C before adding sample loading buffer,
according to the manufacturer’s instructions (New England
Biolabs).
Biotinylation of Cell Surface Proteins
Confluent monolayers were washed 2 times with ice-cold
PBS and cell surface proteins labeled with 1mg/ml Sulfo-NHS-
LC-Biotin in PBS for 30 minutes on ice and at 4°C. Cells were
washed 3 times with ice cold PBS and biotin labeling quenched
by incubating cells with 100mM glycine in PBS for 5 minutes on
ice. After this, cells were carefully washed in ice cold PBS to
remove any residual glycine. Cells were then lysed in LB and
protein concentration determined. 750µg of lysate protein was
incubated for 30 minutes with Streptavidin beads at 4°C, after
which the beads were washed 3 times with LB before adding
denaturing loading buffer and separating by SDS-PAGE.
Supernatant leftover after the streptavidin pull-down was
incubated with anti-BMPR2 antibody (Clone 18, BD) overnight
at 4°C and then subjected to immunoprecipitation with Protein
A/G Plus agarose beads (Santa-Cruz) for 30 minutes.
Immunoprecipitates were washed with LB and proteins eluted
by adding sample loading buffer.
Statistical Analysis
Statistical analyses were performed using one-way ANOVA
with Multiple comparisons between groups and Bonferroni
Comparison test correction post hoc with Graphpad Prism 5
software. Significance is indicated if p<0.05.
Results
Characterization of the BMPR2ΔEx2 mutant protein
product in HPAH patient-derived lymphocytes
To determine if NMD negative BMPR2 mutations are
expressed and incorrectly trafficked to the cell surface in
patients with HPAH, we evaluated BMPR2 protein expression
in HPAH patient-derived lymphocytes [16,30]. Cultured
immortalized lymphocytes were used because these cells are
easily isolated and stored. Additionally, we have a repository of
frozen, HPAH patient-derived cultured lymphocytes at
Vanderbilt from participants in the Vanderbilt Prospective
Pulmonary Hypertension Research Cohort study
[16,19,30,32-35]. For these studies we evaluated BMPR2
expression in lymphocytes derived from an HPAH patient from
Vanderbilt PAH Family 108 (F108) who carry a splice site
mutation predicted to result in an in-frame deletion of BMPR2
EXON2, which encodes residues 26-82 of the 1038 full length
BMPR2 protein[30]. If expressed, the mutant product,
BMPR2ΔEx2, would be distinguishable from the wild type
allelic product by a mobility shift on western blot resulting from
deletion of 56 amino acids encoded by EXON2. We obtained
lymphocytes from one normal control and one F108 HPAH
patient. The anti-BMPR2 antibody, Clone 18, which is a mouse
monoclonal antibody raised against a recombinant fragment
(residues 803-996) from the cytoplasmic tail of human BMPR2
(Figure 1A), detected a strong 130-145 kDa wild type BMPR2
band in control and F108 HPAH patient lymphocytes (Figure
1B). An additional weaker 120 kDa band was detected in F108
HPAH, but not in normal control cells. To determine if the 120
kDa band was the predicted product resulting from in-frame
deletion of BMPR2 EXON2 in F108 HPAH lymphocytes, we
generated an affinity purified rabbit polyclonal anti-BMPR2
Mis-Trafficking of Endogenous BMPR2 Mutant Protein
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antibody, ASQ, raised against the peptide sequence of the first
14 amino acids encoded by BMPR2 EXON2 (Figure 1A). The
130-145 kDa wild type BMPR2 band was detected in control
and F108 lymphocytes, but the 120 kDa BMPR2 band was not
detected in F108 cells using this antibody (Figure 1C). These
data indicate that lymphocytes from a F108 HPAH patient
express a mutant BMPR2 product resulting from an in-frame
deletion of BMPR2 EXON2 (BMPR2ΔEx2).
We next evaluated if the BMPR2ΔEx2 product was
expressed at the cell surface. For this, cell surface proteins
were labeled with a membrane impermeable biotin and
detected by streptavidin pull-down and western blot for BMPR2
using the Clone 18 anti-BMPR2 antibody. The 130-145 kDa
wild type BMPR2 product was detected in the streptavidin pull-
down in control and F108 cultured lymphocytes, but the 120
kDa BMPR2ΔEx2 band was not (Figure 1D, right panel). These
data indicate that the BMPR2ΔEx2 mutant product resulting
from the in-frame deletion of BMPR2 EXON2 in the F108
HPAH patient does not correctly traffic to the cell surface in
cultured lymphocytes.
Characterization of the Bmpr2ΔEx2 product in
pulmonary endothelial cells from Bmpr2ΔEx2/+ mice
To evaluate expression and trafficking of the same,
endogenously expressed, BMPR2ΔEx2 mutant product in a
more physiologically relevant cell type, we isolated
conditionally immortalized pulmonary endothelial cells (ciPECs)
from Bmpr2ΔEx2/+ mice. Bmpr2ΔEx2/+ mice carry the same,
heterozygous in-frame deletion of Exon 2 found in F108 HPAH
patients [26]. The anti-BMPR2 antibody Clone 18 detected a
150 kDa band in control (wild type) and Bmpr2ΔEx2/+ ciPECs, but
an additional 130 kDa band was only detected in the
Bmpr2ΔEx2/+ ciPECs (Figure 2A). To determine if the 130 kDa
band was the predicted product resulting from an in-frame
deletion of Bmpr2 Exon2, we performed western blot analysis
using the anti-BMPR2 antibody ASQ, raised against the
peptide sequence in Exon2 (Figure 1A). The wild type 150kDa
Bmpr2 band was detected in both the control and Bmpr2ΔEx2/+
ciPECs, but the 130kDa product was not detectable in the
Bmpr2ΔEx2/+ciPECs using this antibody (Figure 2B). These data
indicate that Bmpr2ΔEx2/+ ciPECs expressed high levels of the
Bmpr2ΔEx2 mutant product, which is detected as a 130 kDa
band on western blot and is distinct from the 150 kDa wild type
Bmpr2 product.
We performed cell surface biotinylation studies to determine
whether the BmprΔEx2 mutant product was expressed at the
cell surface of Bmpr2ΔEx2/+ciPECs. The 150 kDa wild type
product was detected in the streptavidin pull-down in both
control and Bmpr2ΔEx2/+ ciPECs (Figure 2C). In contrast, the
130 kDa Bmpr2ΔEx2 mutant product was not detected in the
streptavidin pull-down. Additionally, while there was reduced
expression of the wild type Bmpr2 protein in control and
Bmpr2ΔEx2/+ ciPECs in the supernatant remaining after depletion
of cell surface biotinylated proteins by streptavidin pull-down,
expression of the 130kDa Bmpr2ΔEx2 mutant product was not
reduced (Figure 2C, lower panel). These data indicate that like
the 120 kDa BMPR2ΔEx2 product in F108 HPAH patient
Figure 1.  HPAH patient-derived lymphocytes express
mutant BMPR2 products.  A, Schematic of the BMPR2
protein. Areas recognized by the anti-BMPR2 antibodies clone
18 and ASQ are indicated by black arrows. Exons 1-13 are
represented by alternating gray and white boxes, and numbers
indicate corresponding amino acids. LBD, represents the ligand
binding domain, TM the transmembrane domain, KD the kinase
domain and CT the cytoplasmic tail. B, Detection of BMPR2
products in HPAH patient-derived lymphocytes, image
representative of three experiments. Western blot using anti-
BMPR2 antibody, Clone 18. A 130-145 kDa wild type BMPR2
product (WT) was detected in normal control and Family 108
(F108) HPAH patient-derived lymphoblasts. F108 cells
expressed an additional 120 kDa BMPR2 mutant product
(ΔEx2). C, Representative western blot from three experiments
using the ASQ anti-BMPR2 antibody. The 130-145 kDa product
was detected in both control and F108 lymphocytes, but the
120 kDa band was not detected. D, Cell surface expression of
BMPR2 in HPAH patient-derived lymphocytes labeled with a
membrane impermeable biotin. Experiment replicated three
times. Left panel, input cell lysates before the streptavidin pull-
down. Right panel, cell surface proteins detected in streptavidin
pull-down by Western blot using Clone 18 anti-BMPR2
antibody. A 130-145 kDa wild type BMPR2 product was
detected in control and F108 cultured lymphocytes in
streptavidin pull-down but not 120kDa BMPR2ΔEx2 mutant
product.
doi: 10.1371/journal.pone.0080319.g001
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cultured lymphocytes, the 130 kDa Bmpr2ΔEx2 mutant product
does not traffic to the cell surface in Bmpr2ΔEx2/+ ciPECs.
Differential glycosidase sensitivity of the Bmpr2ΔEx
mutant product
We used N-linked glycosidases to determine if the
Bmpr2ΔEx2 mutant product was able to traffic correctly through
Figure 2.  Characterization of the endogenously expressed
Bmpr2 mutant product in pulmonary endothelial cells from
Bmpr2ΔEx2/+ mice.  Studies were performed using conditionally
immortalized PECs (ciPECs) isolated from wild type control
and Bmpr2ΔEx2/+ mice and replicated at least three times. A,
Western blot using the Clone 18 anti-BMPR2 antibody in wild
type (WT) and Bmpr2ΔEx2/+ (ΔEx2/+) ciPEC lysates. Both cell
lines expressed a 150 kDa wild type Bmpr2 product (WT).
Bmpr2ΔEx2/+ ciPECs also expressed a 130 kDa product (ΔEx2).
B, Western blot using ASQ anti-BMPR2 antibody. Wild type
control and Bmpr2ΔEx2/+ ciPECs expressed 150 kDa WT Bmpr2,
but the 130 kDa product was not detected. C, Cell surface
expression of Bmpr2 in ciPECs. ciPECs were labeled with
membrane impermeable biotin and cell surface expression of
Bmpr2 detected in streptavidin pull-down of cell lysates. Anti-
BMPR2 Clone 18 antibody detected the 150 kDa wild type
Bmpr2 in control and Bmpr2ΔEx2/+ ciPECs after streptavidin pull-
down but not the 130kDa Bmpr2ΔEx2 mutant product. Lower
panel, Western blot for Bmpr2 in the supernatant remaining
after depletion of cell surface proteins by streptavidin pull-
down. The ratios of 150 kDa WT Bmpr2 and the 130 kDa
Bmpr2ΔEx2 mutant band intensities in Bmpr2ΔEx2/+ ciPECs
supernatants after depletion of cell surface proteins are
indicated below the lower panel.
doi: 10.1371/journal.pone.0080319.g002
the endoplasmic reticulum (ER) and Golgi apparatus. N-linked
glycosylated proteins that are processed in the ER are
sensitive to Endo-H glycosidase, but become resistant to Endo-
H once the glycoprotein has passed through to the trans-Golgi
[36]. In contrast, PNGase-F de-glycosylates all N-linked
glycosylated proteins irrespective of their maturation state. This
sensitivity to glycosidase digestion can be detected by a
change in protein mobility resulting from cleavage of glycan
moieties. As expected, the 150 kDa wild type Bmpr2 product in
control and Bmpr2ΔEx2/+ ciPECs underwent a mobility shift after
treatment with PNGase-F, but was resistant to Endo-H
digestion (Figure 3). In contrast, the 130 kDa Bmpr2ΔEx2
mutant product underwent a mobility shift after digestion with
PNGase-F and Endo-H (ΔEx2>ΔEx21). This indicates that wild
type Bmpr2 is correctly processed through the ER and Golgi
but that the 130 kDa Bmpr2ΔEx2 mutant product is likely to be
retained in the ER.
Chemical chaperones restore trafficking of the
Bmpr2ΔEx2 mutant product to the cell surface
Since the retention of mutant protein in the ER is often a
consequence of incorrect protein folding [37], we wanted to
evaluate the effects of two chemical chaperones known to aid
in protein folding, 4-PBA and TUDCA [24,25,38-43] , on
trafficking of the Bmpr2ΔEx2 mutant product to the cell surface.
Bmpr2ΔEx2/+ ciPECs treated with increasing concentrations of 4-
PBA show a dose-dependent increase expression of the
130kDa Bmpr2ΔEx2 mutant product in the streptavidin pull-
down (Figure 4A/B). Treatment with 4-PBA also increased the
cell surface expression of the 150 kDa wild type Bmpr2 protein
in Bmpr2ΔEx2/+ ciPECs, but to a relatively lesser extent than
Bmpr2ΔEx2. An aliquot of cell lysates taken before the
streptavidin pull-down showed no change in expression of wild
type Bmpr2 or Bmpr2ΔEx2 with the addition of 4-PBA (Figure
4A, lower panel). An additional chemical chaperone, TUDCA
Figure 3.  Differential N-linked glycosidase sensitivity of
wild type Bmpr2 and Bmpr2ΔEx2 mutant products.  Wild
type control and Bmpr2ΔEx2/+ ciPEC lysates were
immunoprecipitated and digested with N-linked glycosidases
Endo-H or PNGase-F. The 150 kDa wild type Bmpr2 bands in
both control and Bmpr2ΔEx2/+ ciPECs were sensitive to PNGase-
F digestion, determined by a 15 kDa mobility shift (WT>WT1),
but were insensitive to Endo-H digestion. Unlike wild type
Bmpr2, the 130 kDa Bmpr2ΔEx2 mutant product in Bmpr2ΔEx2/+
ciPECs was sensitive to Endo-H digestion (ΔEx2>ΔEx21).
doi: 10.1371/journal.pone.0080319.g003
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added to cells prior to biotinylation also increased cell surface
expression of the 130kDa Bmpr2ΔEx2 mutant protein in
Bmpr2ΔEx2/+ ciPECs (Figure 4C/D). There was also a small
increase in cell surface expression of wild type Bmpr2 after
treatment with TUDCA (a 1.4 fold increase with 500µM TUDCA
versus untreated cells). These data indicate that chemical
chaperones increase cell surface expression of Bmpr2ΔEx2 in
Bmpr2ΔEx2/+ ciPECs, and suggest that ER retention of
Bmpr2ΔEx2 results from mis-folding of the mutant protein.
BMP signaling defects in primary pulmonary
endothelial cells from Bmpr2ΔEx/+ mice
To determine the functional effects of the Bmpr2ΔEx2/+
mutation on BMP-mediated signaling responses, we evaluated
BMP signaling in early passage primary pulmonary endothelial
cells (PECs). For this, six separate PEC isolates were prepared
from 3 wild type control and 3 Bmpr2ΔEx2/+ mice. There was a
significant decrease in BMP-stimulated phospho-Smad1/5/8
expression in Bmpr2ΔEx2/+ PECs associated with reduced basal
and BMP-induced Id1 expression (Fig. 5A/B/C). There was
also an increase in phospho-Erk1/2 expression in Bmpr2ΔEx2/+
PECs (Figure 5A/D) but no significant change in phospho-Akt
Figure 4.  Chemical chaperones partially restore Bmpr2ΔEx2 mutant product expression at the cell surface.  A, Cell surface
expression of Bmpr2ΔEx2 in Bmpr2ΔEx2/+ ciPECs treated with 4-PBA. Bmpr2ΔEx2/+ ciPECs were treated for 48 hours with 100µM,
250µM, 500µM or 1mM of 4-PBA. Monolayers were then labeled with membrane impermeable biotin and biotinylated cell surface
proteins pulled-down with streptavidin agarose beads. Western Blot was performed with Clone 18 anti-BMPR2 antibody. The 150
kDa wild type Bmpr2 product was detected in the streptavidin pull-down in control and Bmpr2ΔEx2/+ ciPECs, but the 130 kDa
Bmpr2ΔEx2 mutant product was not detected. After treating with the chemical chaperone 4-PBA, the 130kDa Bmpr2ΔEx2 mutant
product was detected and there was increased expression of the wild type Bmpr2 product in the streptavidin pull-down. Numbers
shown below the upper panel indicate the ratio of the 130 kDa Bmpr2ΔEx2 band before and after treatment with 4-PBA. Lower
panel, expression of wild type Bmpr2 and Bmpr2ΔEx2 in ciPEC cell lysates with 4-PBA treatment. B, Quantification of wild type
Bmpr2 and Bmpr2ΔEx2 band densities after 4-PBA treatment relative to untreated controls from three independent experiments,
standard error is indicated. C, Cell surface expression of Bmpr2ΔEx2 in Bmpr2ΔEx2/+ ciPECs treated with TUDCA. Wild type and
Bmpr2ΔEx2/+ ciPECs were treated for 5 hours with 50µM 100µM, 250µM or 500µM of TUDCA. Streptavidin pull-down shows that the
130kDa Bmpr2ΔEx2 mutant product was partially restored at the cell surface and there was a slight increase in wild type Bmpr2 with
TUDCA treatment (1.4 fold increase with 500µM TUDCA versus untreated cells). Numbers shown below the upper panel indicate
the ratio of the 130 kDa Bmpr2ΔEx2 band before and after treatment with TUDCA Lower panel, expression of wild type Bmpr2 and
Bmpr2ΔEx2 in ciPEC cell lysates with TUDCA treatment. D, Quantification of wild type Bmpr2 and Bmpr2ΔEx2 band densities after
TUDCA treatment relative to untreated controls from three independent experiments.
doi: 10.1371/journal.pone.0080319.g004
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(Figure 5A/E). These studies indicate that Bmpr2ΔEx2/+ PECs
exhibit BMP signaling defects.
Figure 5.  BMP signaling defects in primary pulmonary endothelial cells from Bmpr2ΔEx2/+ mice.  Primary PECs were isolated
from 3 different wild type control (WT) and 3 Bmpr2ΔEx2/+ mice (ΔEx2). A, Western blot of cell lysates isolated from wild type control
(W1-W3) and Bmpr2ΔEx2/+ (E1-E3) PECs treated with 10ng/ml BMP2 for 4 hours. Antibodies indicated on the right. Densitometry for
phospho-Smad1/5/8 (B), Id1 (C), pERK1/2 (D) and pAKT bands (E). Results expressed as mean +/- SEM, 3 per group. One-way
ANOVA with post hoc Bonferroni correction, p<0.05 *WT +/-BMP2; **ΔEx2+/-BMP2; ***WT vs. ΔEx2. Experiment and isolation of
primary PECs was replicated four times.
doi: 10.1371/journal.pone.0080319.g005
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Chemical Chaperone 4-PBA restores BMP signaling
defects in Bmpr2ΔEx2/+ PECs
To determine whether restoration of cell surface expression
of Bmpr2ΔEx2 restores defective BMP signaling in Bmpr2ΔEx2/+
PECs, we evaluated BMP signaling primary PECs isolates
obtained from 1 wild type control and 3 Bmpr2ΔEx2/+ mice
treated with 4-PBA (Figure 6A). 4-PBA restored BMP2 induced
Smad1/5/8 phosphorylation (Figure 6B) and BMP-induced Id1
protein expression in Bmpr2ΔEx2/+ PECs to a level comparable
to that seen in wild type PECs treated with BMP2 (Figure 6C).
These data indicate that treatment with the chemical
chaperone 4-PBA restores the defective BMP-Smad/Id1
signaling axis in Bmpr2ΔEx2/+ PECs.
Discussion
In these studies, we provide the first evidence that an NMD
negative BMPR2 mutation found in patients with HPAH is
expressed endogenously, and that this mutant protein product
is mis-folded and incorrectly trafficked to the cell surface. We
also show that chemical chaperones partially restore cell
surface expression of the same Bmpr2 mutant product in
pulmonary endothelial cells from mice carrying the same
heterozygous germ line mutation, and that treatment with
chemical chaperones rescues the associated BMP signaling
defects in these cells. These data provide the first evidence for
the therapeutic use of chemical chaperones to correct
endogenous signaling defects resulting from mis-folded
BMPR2 mutant products in patients with HPAH.
Our studies focus on the expression and trafficking of these
BMPR2 mutant products in pulmonary endothelial cells from
Bmpr2ΔEx2/+ mice since BMPR2 is highly expressed in
endothelial cells in the pulmonary vasculature, and endothelial
expression of BMPR2 has been implicated in maintaining
normal pulmonary vasculature tone and integrity
[8,11,13,14,44,45]. We have also previously shown that mice
with heterozygous in-frame deletion of Bmpr2 Exon2
(Bmpr2ΔEx2/+) have reduced endothelium-dependent vasodilator
responses in the pulmonary vasculature [8], and approximately
Figure 6.  Treatment with 4-PBA rescues signaling defects in Bmpr2ΔEx2/+ pulmonary endothelial cells.  Individual primary
PECs isolates obtained from 1 wild type control and 3 Bmpr2ΔEx2/+ mice were treated with 1mM 4-PBA for 48 hours followed by
BMP2 treatment for 4 hours, as indicated. A, Western blot for phospho-Smad1/5/8 and Id1 shows 4-PBA restores phospho-
Smad1/5/8 and Id1 expression in Bmpr2ΔEx2/+ PECs to expression levels similar to BMP-stimulated WT PECs. B, Densitometry for
phospho-Smad1/5/8 and C, Id1 expressed as ratio to total Smad1 and β-actin respectively. Results expressed as mean +/- SEM of
three individual PEC isolates per group. One-way ANOVA with post hoc Bonferroni correction, p<0.05 * ΔEx2/+ +BMP2 vs. ΔEx2/+
+BMP2+4-PBA.
doi: 10.1371/journal.pone.0080319.g006
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30% of mice with conditional ablation of Bmpr2 in endothelial
cells develop spontaneous pulmonary hypertension [11]. These
findings suggest that endothelial BMPR2 plays an important
role in the regulating pulmonary vascular function, and
suggests strategies to correct BMP signaling in pulmonary
endothelial cells may have beneficial effects on the pulmonary
vasculature in mice and HPAH patients with BMPR2 mutations.
We found that the Bmpr2ΔEx2 mutant product was
expressed at high levels in pulmonary endothelial cells isolated
from Bmpr2ΔEx2/+ mice. The identity of this band was verified as
the in-frame deletion of Exon2 by using an antibody raised
against the peptide sequence encoded by BMPR2 Exon2
(ASQ). This in-frame deletion of Exon2 is also expressed in the
F108 HPAH patient-derived lymphocytes. However, there are
differences in mobility of both wild type BMPR2 and the
BMPR2ΔEx2 products in mouse ciPECs and cultured human
lymphocytes. This is likely due to cell-type dependent
differences in post-translational modifications/glycosylation of
BMPR2. In addition, unlike F108 HPAH patient–derived
lymphocytes, the presumed Bmpr2ΔEx2 mutant product in
Bmpr2ΔEx2/+ ciPECs had an expression level similar to the 150
kDa wild type Bmpr2 product. This indicates that there are cell-
type dependent differences in expression of the mutant allelic
products, and that high levels of Bmpr2ΔEx2 expression in
endothelial cells may exert more profound effects on cellular
function than in different cell types. Cell surface biotinylation
and N-glycosidase sensitivity assays indicate that the
Bmpr2ΔEx2 mutant product does not traffic correctly to the cell
surface and is retained in the ER. Additionally, chemical
chaperones 4-PBA and TUDCA, agents that are known to aid
in protein folding [24,25,38-43], partially restore trafficking of
the Bmpr2ΔEx2 mutant product to the cell surface. These
findings suggest that the Bmpr2ΔEx2 is retained in the ER as a
result of mis-folding of the mutant product. Since deletion of
Exon2 in Bmpr2ΔEx2 results in a loss of 3/10 cysteine residues
located in the ligand-binding domain of Bmpr2, it is likely that
mis-folding occurs as a result of a breakdown in paired
cysteine disulfide bond formation which is required for correct
Bmpr2 structure and folding in the ER [46-49].
Our data suggest that chemical chaperones may be used to
correct BMP signaling defects in HPAH patients with NMD
negative BMPR2 mutations. Functional studies show that 4-
PBA treatment can restore CFTR receptor ΔF508 mutant
trafficking and function in cells derived from Cystic Fibrosis
(CF) patients [25], and 4-PBA has recently been used in clinical
trials as a chemical chaperone to treat CF [50,51]. Treatment
with chemical chaperones like 4-PBA aid in protein folding and
trafficking to the cell surface; however it is important to note
that there are a number of NMD negative BMPR2 mutations
located in regions of the protein that would not benefit from
trafficking to the cell surface. For example, mutations located in
the kinase domain or cytoplasmic tail domains of BMPR2 in
particular may not benefit from chaperone treatment. For this
strategy to work in HPAH patients with NMD negative BMPR2
mutations, the mutations must allow at least partial BMPR2
function when the mutant product is expressed at the cell
surface. Correcting a protein-folding defect of an HPAH NMD
negative BMPR2 mutant product that has dominant negative
activity when expressed at the cell surface might have adverse
effects on BMP signaling. This has been demonstrated with the
kinase inactive HPAH BMPR2 C483R mutation in in a
heterologous over-expression system [23], but still needs to be
evaluated endogenously in HPAH patient-derived cells. In the
case of Bmpr2ΔEx2, correction of BMP signaling defects by
chemical chaperones may be occurring through two non-
mutually exclusive mechanisms. While the Bmpr2ΔEx2
mutation interferes with the structure of the ligand-binding
domain of the receptor (and presumably therefore interferes
with ligand binding to the receptor), Bmpr2ΔEx2 may still
participate in functional hetero-tetrameric complexes with wild
type BMPR2 and other BMP Type 1 receptors that can
independently directly engage BMP ligands at the cell surface.
Interestingly, 11% of NMD negative BMPR2 mutations are in
the ligand-binding domain of BMPR2 [18], and may similarly
benefit from corrected trafficking to the cell surface. However,
in addition to restoring cell surface expression of the mutant
allelic product, our data show that 4-PBA, and to a lesser
extent TUDCA, increase cell surface expression of wild type
Bmpr2 in Bmpr2ΔEx2/+ ciPECs. Since mis-folding of Bmpr2ΔEx2
may trap some wild type Bmpr2 in the ER, it is possible that
this effect is a direct consequence of 4-PBA-dependent
correction of the cell surface trafficking defect of the mutant
allele. Given that expression levels of Bmpr2 have been shown
to be important in maintaining normal signaling function [2,35],
this increase in expression of wild type Bmpr2 protein at the
cell surface may account for the restoration in BMP signaling in
Bmpr2ΔEx2/+ ciPECs after treatment with chemical chaperones.
However, irrespective of the mechanisms restoring BMP
signaling in Bmpr2ΔEx2/+ ciPECs, our data indicate that there
may be a subset of HPAH patients with NMD negative BMPR2
mutations that show beneficial responses to protein folding
agents. Further analysis of endogenous BMPR2 mutant
product folding and signaling defects in HPAH patients carrying
different NMD negative BMPR2 mutations will have to be
performed to determine which patients might benefit from this
therapy.
Our studies provide the first evidence that chemical
chaperones can be used to rescue BMP signaling defects
associated with endogenously expressed NMD negative HPAH
BMPR2 mutations in the pulmonary endothelium. Additionally,
the chemical chaperones we evaluated, 4-PBA and TUDCA,
are FDA-approved drugs and commercially available
supplements, respectively, and are in clinical trials for other
diseases caused by mis-folded proteins [50-52]. Therefore,
while further analysis of endogenous BMPR2 mutant product
folding and signaling defects in HPAH patients will have to be
performed to determine which patients might benefit from this
therapy, our data suggest an additional disease modifying
therapy that may benefit a subset of HPAH patients with NMD
negative BMPR2 mutations.
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